Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia.
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.
Kalff
A
A
Department of Clinical Haematology and Bone Marrow Transplantation, The Alfred Hospital, Melbourne, Australia.
Shortt
J
J
Farr
J
J
McLennan
R
R
Lui
A
A
Scott
J
J
Spencer
A
A
D018450:Disease Progression; D004573:Electrolytes / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D017809:Fatal Outcome; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry / Q000494:pharmacology*; D007211:Indoles; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000077767:Panobinostat; D015275:Tumor Lysis Syndrome / Q000150:complications / Q000209:etiology*
D004573:Electrolytes; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat